Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated plasmodium falciparum malaria in travelers

Shirly Grynberg, Tamar Lachish, Eran Kopel, Eyal Meltzer, Eli Schwartz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Atovaquone-proguanil (AP) and artemether-lumefantrine (AL) are both treatments for uncomplicated Plasmodium falciparum malaria, but comparative clinical trials are lacking. We performed a retrospective analysis, comparing treatment failure and fever clearance time in non-immune travelers with uncomplicated P. falciparum malaria, treated with AP or AL. Sixty-nine patients were included during 2001-2013: 44 in the AP group and 25 in the AL group. Treatment failure was observed in 6 of 44 (13.6%) and 1 of 25 (4.0%) patients in the AP and AL groups, respectively. Six treatment failures were observed in travelers from West Africa. Fever clearance time was 44 ± 23 h in AL group versus 77 ± 28 h in AP group, (P < 0.001). Hospitalization time was significantly shorter in the AL group; 3.8 + 1.3 versus 5.1 + 2.8 days in the AP group (P = 0.04) In conclusion, travelers with uncomplicated P. falciparum malaria recover faster on AL than on AP. The AL should probably be the drug of choice for this population.

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume92
Issue number1
DOIs
StatePublished - 1 Jan 2015

Fingerprint

Dive into the research topics of 'Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated plasmodium falciparum malaria in travelers'. Together they form a unique fingerprint.

Cite this